XS
CYTK icon

XR Securities’s Cytokinetics CYTK Stock Holding History

XR Securities’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,900
Closed -$1.41M – 363
2023
Q4 		$1.41M Buy
+16,900
New +$612K 0.05% 152

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

XR Securities's CYTK Position: Q2 2024 in Review

XR Securities sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 18,373 shares — an estimated $1.29M sold.

XR Securities first reported a position in CYTK in Q1 2024 and held it in 1 quarter. The position peaked at $1.29M in Q1 2024. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • XR Securities reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • XR Securities sold 18,373 Cytokinetics shares in Q2 2024, an estimated $1.29M.
  • XR Securities first reported a position in Cytokinetics in Q1 2024 and held it in 1 quarter.
  • XR Securities's Cytokinetics position peaked at $1.29M in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on XR Securities's 13F filing for Q2 2024, filed 5 Aug 2024.